Congratulations to Arsenal Biosciences, Inc., who in April announced the First Patient Dosed in Phase 1/2 for AB-2100 in development as a treatment for clear-cell renal cell carcinoma. https://lnkd.in/gtNyhKKh
AbCellera’s Post
More Relevant Posts
-
⚡️ New Phase 3 TiNivo-2 Study Results: Tivozanib nivolumab versus tivozanib monotherapy in patients with advanced renal cell carcinoma post-immune checkpoint inhibitors. Findings suggest that ICI rechallenge may not be optimal after progression, highlighting the efficacy of tivozanib monotherapy in this setting. #KidneyCancer #Immunotherapy https://buff.ly/3BcuRVm
To view or add a comment, sign in
-
【Nivolumab ipilimumab demonstrates long-term survival benefits as a first-line treatment for patients with previously untreated advanced renal cell carcinoma】 Read now: https://lnkd.in/gdq6gVw3 With a median follow-up of 99.1 months, the recent analysis of the CheckMate 214 trial serves as the longest reported follow-up for any phase 3 trial of a checkpoint inhibitor combination therapy in advanced renal cell carcinoma (aRCC), which demonstrated the remarkable and durable clinical responses of nivolumab ipilimumab as a first-line therapy for untreated aRCC.
To view or add a comment, sign in
-
Keytruda becomes the first immuno-oncology agent to show an overall survival benefit in adjuvant renal cell carcinoma. Bristol gains ground on Merck and Roche in race to develop a subcutaneous checkpoint inhibitor. https://lnkd.in/eCPfKsc9
To view or add a comment, sign in
-
BeiGene's PD-1 inhibitor Tevimbra receives FDA approval- turning a new page in oncology! BeiGene has gained FDA approval for its PD-1 inhibitor, Tevimbra, after a long regulatory process spanning over two years. Tevimbra, also known as tislelizumab, will be available in the US for treating metastatic esophageal squamous cell carcinoma (ESCC) after prior chemotherapy in the latter half of 2024. Despite previous delays due to Covid-related travel restrictions and changes in ownership, Tevimbra's efficacy was well demonstrated in clinical trials, leading to its approval as the 10th FDA-approved PD-(L)1 drug. BeiGene aims to establish itself as a leading player in oncology with further FDA decisions expected for Tevimbra's use in other indications later this year, allowing them to expand their immuno-oncology portfolio. Read Full Article Here: https://lnkd.in/djDr4xyY #innovation #business #lifescience #biopharma #healthcare #global #regional #collaboration #crossborder #jointventure #investing #biothechnology #bitech #phamaceuticals #capitalmarket #stockmarket #venturecapital #fundraising #globaltrade #economy #economics #creativity #technology #raredisease #drugdevelopment #drugdiscovery #pharmaindustry #biopharmaceutical #mentalhealth #oncology #nuerology #cns #autoimmune #endocrinology #cardiovascular #immunology #gynecology #pulmonology #gastroenterology #anesthesiology #urology #cardiovascular #china #japan #korea #israel #latinameica #australia #europe #usa #shanghai #FDAapproval #Tevimbra # BeiGene
We are excited to announce the FDA has approved our medicine for the treatment of advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. This represents an exciting step forward for patients. Learn more about this important milestone: https://bit.ly/4agtZvh
To view or add a comment, sign in
-
Renal Cell Carcinoma Illustration showing the enhancement of renal cell carcinoma across the 4 phases of CT. https://lnkd.in/eui6ynYx
To view or add a comment, sign in
-
MSAT Scientist I Personalized Medicine I Ai/ML| hiPSCs stem cells | Analytics & QC | cGMP | Cell & Gene Therapy | CAR-T ♋I CAR-T | ImmunoTherapy | Gene editing CRISPR🧬✂️ #CAR-T🔬🦠🩸🫁🫀|
💥Do you know why the warning label has only been altered for Carvykti? 💥The FDA has updated the warning label for Legend Biotech and Janssen's myeloma CAR-T treatment, Carvykti (cilta-cel), to include information about the occurrence of secondary blood cancers in some patients treated for multiple myeloma with this cell therapy. 💥Although this new label necessitates discussions between doctors and patients regarding the potential risk of secondary malignancies after using Carvykti, oncologists and experts in CAR-T therapy believe this update will not affect how Carvykti is used. 💥relevant concern on second malignancies after CAR-T therapy in MM But difficult to conclude
To view or add a comment, sign in
-
Update on phase III LEAP-001 trial evaluating Keytruda (pembrolizumab) Lenvima (lenvatinib) as first-line treatment for advanced or recurrent endometrial carcinoma - Merck Inc Eisai https://lnkd.in/eE_mW2T9
To view or add a comment, sign in
-
The correct choice of systemic therapy for unresectable hepatocellular carcinoma could be challenging due to the variability of the response to treatment! In this scenario fits our Editorial entitled "Tislelizumab: a promising alternative first-line systemic therapy in unresectable advanced hepatocellular carcinoma" that briefly describes the different first-line therapeutic opportunities, includingTislelizumab, a new emerging and promising drug in this field. Now available online: https://lnkd.in/d_ev9gjJ Enjoy your reading! #hepatocellularcarcinoma #hcc #livercancer #immunotherapy #studyliver
Tislelizumab: a promising alternative first-line systemic therapy in unresectable advanced hepatocellular carcinoma
actr.amegroups.org
To view or add a comment, sign in
-
Sarcoma is a rare and often aggressive cancer. Awareness and early diagnosis are vital for improving survival rates. Being aware and being vigilant on the signs of Sarcoma is key to early detection and can lead to timely treatment and better outcomes. We at Eisai Pharmaceuticals India are committed to spread awareness on Sarcoma. Together, we can make a significant impact, Like/share/repost! #Sarcoma #SarcomaAwareness #EarlyDiagnosis #HealthMatters #SaveLives @ EisaiUS
To view or add a comment, sign in
-
CytoAgents’ drug candidate, CTO1681, prevents and treats Cytokine Release Syndrome (CRS), which is a dangerous side effect to CAR T-cell therapy in oncology. CTO1681 targets the NF-kB signaling pathway via the activation of the EP4 receptor, which reduces NF-kB signaling, but does not shut it down completely. This, in turn, modulates cytokine production, resulting in reduced inflammation, while still allowing for a functioning immune system. Learn more about CRS and CTO1681 here: https://lnkd.in/eFasArrf #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh
To view or add a comment, sign in
35,662 followers